BioGaia AB - Company Profile
Powered by 
All the data and insights you need on BioGaia AB in one report.
$295
- Save hours of research time and resources with
our up-to-date BioGaia AB Strategy Report
- Understand BioGaia AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), straws, and infant formulas. The company's major product areas include baby and child gut health, adult gut health, probiotic gastrointestinal health, oral health and bone health. BioGaia's products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. Its products improve the digestive and oral health of children and adults and controls digestive problems such as colic, regurgitation, diarrhoea and constipation. The company sells its products through distributors in the Americas, Europe and Asia-Pacific. BioGaia is headquartered in Stockholm, Sweden.
Headquarters
Sweden
Address
Kungsbroplan 3, Stockholm, 11227
Website
sv.biogaia.com
Telephone
46 8 55529300
No of Employees
210
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BIOG B (STO)
Revenue (2022)
$122.2M
17.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-2.3%
(2022 vs 2021)
Market Cap*
$1.1B
Net Profit Margin (2022)
XYZ
-16.8%
(2022 vs 2021)
* As of and is in US$
BioGaia AB premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Baby and Child Gut Health: | BioGaia |
| BioGaia Protectis Baby Drops (Easy Dropper) | BioGaia Pharentis |
| BioGaia Protectis Tabs | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In March, the company launched a probiotic skin ointment for infants and children. |
| 2022 | Acquisitions/Mergers/Takeovers | In October, the company acquired Everidis. |
| 2022 | Contracts/Agreements | In August, the company and MetaboGen entered into an agreement to open a pilot plant in Eslov for fermentation. |
Competitor Comparison
| Key Parameters | BioGaia AB | Camurus AB | Probi AB | Bifodan A/S | Essum AB |
|---|---|---|---|---|---|
| Headquarters | Sweden | Sweden | Sweden | Denmark | Sweden |
| City | Stockholm | Lund | Lund | Hundested | Umea |
| State/Province | - | - | - | - | Vasterbotten |
| No. of Employees | 210 | 213 | 160 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Rothschild | Chairman | Executive Board | 2018 | 73 |
| Theresa P. Agnew | Chief Executive Officer | Senior Management | 2023 | - |
| Alexander Kotsinas | Executive Vice President; Chief Financial Officer | Senior Management | 2019 | 56 |
| Ludvig Milesson | Chief Operating Officer | Senior Management | 2023 | 46 |
| Caroline Mofors | Chief Legal Officer | Senior Management | 2023 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward